Drugs for treating breast cancer in women are effective and well tolerated in men
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - There is growing evidence that drugs approved for the treatment of breast...
NEWS INDEX
Major trial shows targeted drug extends breast cancer survival
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found. Women taking palbociclib...
New option for women with advanced breast cancer resistant to hormone therapy
Credit: © European Society for Medical Oncology Munich, Germany, 20 October 2018 - Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a...
Some patients with metastatic triple negative breast cancer live longer with immunotherapy
Credit: © European Society for Medical Oncology Munich, Germany, 20 October 2018 - Immunotherapy improves survival in some patients with metastatic triple negative breast cancer,...
Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Munich, Germany, 21 October 2018 - Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small...
PROs indicate brachytherapy alone is the superior treatment
Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy (EBT+B) to transperineal interstitial permanent brachytherapy (B) alone indicate a significantly...
Interaction of pretreatment immune inflammatory state of patient outcomes following RT
Data from a validation study of NRG-RTOG 0521 suggests that, while there is no association between an elevated level of C-reactive protein (CRP) and disease-free...
Radiation therapy cuts low risk of recurrence in half for patients with good risk breast cancer
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even...
Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase...
Study shows childhood obesity the major risk factor for serious hip disease
New research suggests that rising childhood obesity rates are causing more adolescents to develop a debilitating hip disease requiring urgent surgery. Slipped Capital Femoral Epiphysis...
Local radiotherapy improves survival in metastatic prostate cancer with low disease burden
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - Radiotherapy to the prostate improves overall survival in men newly diagnosed with...
3D bioprinting technique could create artificial blood vessels, organ tissue
University of Colorado Boulder engineers have developed a 3D printing technique that allows for localized control of an object's firmness, opening up new biomedical avenues...
Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor,...
Home-based biofeedback therapy is effective option for tough-to-treat constipation
Credit: Phil Jones, Senior Photographer, Augusta University AUGUSTA, Ga. (Oct. 22, 2018) - Biofeedback therapy used at home is about 70 percent effective at helping...
HIV-infected Hispanic adults face higher risks of HPV-related cancers
A new study reveals that Hispanic HIV-infected adults in the United States are at a higher risk of developing cancers caused by the human papillomavirus...
POPULAR NEWS
-
Saying Goodbye to PGY-6: Pediatric Fellowship Realities
-
Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates
-
Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks
-
New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer